TetraLogic公布第三季度财务业绩，并提供临床项目

StephenW

TetraLogic Reports Third Quarter Financial Results and Provides Clinical Programs Update   
                             
                                       
                           
                                            
            
        
                                                                                November 05, 2014 16:36 ET                                     | Source:  TetraLogic Pharmaceuticals                                             
                                     MALVERN, Pa., Nov. 5, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, today announced financial results for the third quarter ended September 30, 2014. These results are included in TetraLogic's Quarterly Report on Form 10-Q which has been filed with the Securities and Exchange Commission.
        "This year we have advanced all of our clinical programs," said J. Kevin Buchi, President and Chief Executive Officer of TetraLogic. "First, based on in-vivo data indicating clearance of both hepatitis B DNA and surface antigen (HBsAg), we are advancing birinapant into the clinic in the study for the treatment of chronic hepatitis B. Second, in myelodysplastic syndrome (MDS), we were encouraged by the previously announced Phase 1 data and have commenced enrollment in a Phase 2 trial, to further evaluate the activity of birinapant in combination with standard of care azacitidine. Third, enrollment continues in our signal seeking study of birinapant in combination with Amgen's conatumumab, a TRAIL agonist antibody, in ovarian cancer patients. Finally, we are advancing SHAPE, our novel, topical HDAC inhibitor, into a randomized Phase 2 clinical trial to evaluate its activity in early stage cutaneous T-cell lymphoma (CTCL)."
        Summary of Key Development Programs, Updates and Anticipated Milestones

•                 Birinapant HBV Program: In a mouse model we have generated data demonstrating that birinapant induces apoptosis in mouse hepatocytes infected with hepatitis B, while sparing normal hepatocytes.  In the mouse model we have seen clearance of HBsAg. We are commencing enrollment in a multiple ascending dose study of birinapant in subjects with chronic hepatitis B in the fourth quarter of 2014.  We currently expect data to be generated around the middle of 2015.  The trial will be conducted in subjects over the age of 18 with hepatitis B who are receiving treatment with either tenofavir or entecavir and who are HBsAg positive.  The trial is expected to enroll approximately 6 cohorts of 8 subjects each, who will receive 4 weekly treatments with either birinapant or placebo in a 3:1 ratio.  The study is being conducted at multiple clinical sites in Australia and New Zealand.  Although predominantly a safety and tolerability study, patients will also be monitored for reductions in hepatitis B surface antigen as an indication of therapeutic activity. On November 10, 2014, TetraLogic will be discussing its HBV program at an investor forum at the American Association for the Study of Liver Diseases Conference.
•                 Birinapant MDS Program:  In May, we announced that, based upon data from our Phase 1b study of birinapant in combination with azacitidine in patients with higher risk MDS who are either relapsed/refractory or naïve to azacitidine, we initiated a randomized Phase 2 clinical trial in first line higher risk patients. While the primary objective of the Phase 1b clinical study was to characterize the safety and tolerability and determine the recommended Phase 2 dose of birinapant when administered in combination with azacitidine, we did observe bone marrow responses in a number of patients who had relapsed or were refractory to azacitidine.  We currently expect interim data from the Phase 2 study in the middle of 2015.
•                 SHAPE CTCL Program: In May, safety and efficacy data from the Phase 1b randomized placebo controlled clinical study of SHAPE, our topical HDAC inhibitor, in Stage IA –IIA Cutaneous T-cell Lymphoma (CTCL) were presented at the annual Society of Investigative Dermatology meeting and at American Society of Clinical Oncology meeting.  We are advancing SHAPE into a randomized Phase 2 clinical trial in early stage CTCL.  We currently expect data around the end of 2015.
•                 Birinapant/conatumumab Program:  Enrollment continues in a signal-seeking study in combination with conatumumab, Amgen's TRAIL agonist antibody, in 3rd line ovarian cancer.  We currently expect data around the end of 2014.
  

        Third Quarter 2014 Financial Highlights

•                 Cash, cash equivalents, and marketable securities totaled $65.1 million at September 30, 2014, as compared to $55.1 million at December 31, 2013.
•                 Research and Development expenses were $5.7 million for the third quarter of 2014, excluding $0.2 million in non-cash, stock based compensation expense, compared to $2.1 million for the same period in 2013. The increase primarily results from additional costs associated with clinical trials, including the manufacturing and formulation of our clinical drug supplies.
•                 General and Administrative expenses were $2.0 million for the third quarter of 2014, excluding $0.6 million in non-cash, stock based compensation expense, compared to $1.9 million for the same period in 2013, excluding $0.3 million in non-cash, stock based compensation expense.
•                 Adjusted net loss for the third quarter of 2014 was $8.6 million, compared to an adjusted net loss of $4.2 million for the same period in 2013. Adjusted net loss excludes (i) non-cash stock based compensation expense; (ii) non-cash interest expense; (iii) non-cash fair value adjustments to the company's derivative liabilities: and (iv) non-cash fair value adjustments to the contingent consideration liability recognized as part of the Shape acquisition in April 2014.
•                 Shares issued and outstanding as of September 30, 2014 were 22.3 million, not including outstanding stock options to purchase 3.2 million shares and 7.0 million shares underlying the company's outstanding convertible notes.
  

        Non-GAAP Financial Measures
        In the attached press release, the Company discloses "Adjusted net loss," "Basic adjusted net loss per common share," and "Diluted adjusted net loss per common share" for certain historical periods, all of which are considered "non-GAAP financial measures" under Securities and Exchange Commission rules. A "non-GAAP financial measure" is defined as a numerical measure of a company's historical or future financial performance, financial position or cash flows that excludes (or includes) amounts, or is subject to adjustments that have the effect of excluding (or including) amounts, that are included in (or excluded from) the most directly comparable measure calculated and presented in accordance with GAAP in the Company's financial statements. Management does not intend the presentation of non-GAAP financial measures to be considered in isolation or as a substitute for results prepared in accordance with GAAP.
        For all periods presented, the Company reconciles net loss on a GAAP basis to adjusted net loss. Management believes that the presentation of these adjusted measures is useful to investors because it provides a means of evaluating the Company's operating performance and results from period to period on a comparable basis not otherwise apparent on a GAAP basis, since many non-cash, infrequent, or unusual charges, including items that may not affect the Company's operations, do not meet the strict GAAP definition of unusual non-recurring items. Furthermore, in preparing operating plans, budgets and forecasts, and in assessing historical performance, management relies, in part, on trends in the Company's historical results, exclusive of these items. Finally, management believes that this presentation is useful in facilitating comparisons between the Company and other companies in its industry, many of whom exclude similar items.
        About TetraLogic Pharmaceuticals Corporation
        TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases.  TetraLogic has two clinical-stage product candidates in development: birinapant and SHAPE. Birinapant is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors, and is also entering a Phase 1b/2a clinical trial in hepatitis B.  SHAPE is entering a Phase 2 clinical trial for early-stage Cutaneous T-cell Lymphoma.

StephenW

TetraLogic公布第三季度财务业绩，并提供临床项目
2014年11月5日16时36分ET|来源：TetraLogic制药

宾夕法尼亚，MALVERN，2014年11月5日（GLOBE NEWSWIRE） -  TetraLogic制药公司（纳斯达克股票代码：TLOG），临床阶段的生物制药公司，主要致力于发现和开发肿瘤和感染性疾病的新型小分子疗法，今天公布的财务业绩9月30日，截至2014年第三季度这些结果表格中包含TetraLogic的季度报告已经提交给美国证券交易委员会的10-Q表。

“今年，我们拥有先进的我们所有的临床项目，”J.凯文步琪，总统和TetraLogic的首席执行官说。 “首先，在体内的数据表明两者乙肝DNA和表面抗原（HBsAg）的清除，我们正在推进birinapant进入临床研究中用于治疗慢性乙型肝炎。其次，在骨髓增生异常综合征（MDS）的治疗基础上，我们在此前公布的一期数据进行了鼓励，并在第2阶段试验开始招生，以进一步评估与护理阿扎胞苷的标准组合birinapant的活动;第三，招生将继续在我们的信号求birinapant的研究，结合Amgen公司conatumumab中，TRAIL受体激动剂抗体，在卵巢癌患者。最后，我们正在前进形状，我们的新颖的，局部的HDAC抑制剂，成随机的2期临床试验，以评估其活性的早期皮肤T细胞淋巴瘤（CTCL）“。

重点发展项目，更新和预期里程碑摘要

    Birinapant乙肝病毒程序：在小鼠模型中，我们已经生成的数据表明，birinapant诱导凋亡在感染乙型肝炎小鼠肝细胞，同时保留正常肝细胞。在小鼠模型中，我们所看到的HBsAg的间隙。我们开始招生birinapant的倍数递增剂量研究中受试者慢性乙型肝炎在2014年第四季度，我们目前预计约于2015年，中间产生的数据的试验将在主体18岁以上进行乙肝谁正在接受与任何tenofavir或恩替卡韦，谁是HBsAg阳性的治疗。该试验预计招募近6同伙各8名受试者，谁将会收到任何birinapant或安慰剂34周的治疗：1的比例。这项研究是在澳大利亚和新西兰多个临床中心进行中。虽然主要是一个安全和耐受性研究中，患者也将被用于减少乙肝表面抗原作为治疗活性的指征监测。 11月10日2014年，TetraLogic将在一个投资者论坛在美国协会为肝病大会将研究讨论了乙肝项目。
     
    Birinapant MDS方案：5月，我们宣布，基于从birinapant在与阿扎胞苷患者的高危MDS结合我们的阶段1b研究数据谁不是复发/难治性或天真的阿扎胞苷，我们发起了一个随机的2期临床试验在第一行风险较高的患者。虽然1B临床研究阶段的主要目标是表征的安全性和耐受性，并确定推荐的二期剂量birinapant时与阿扎胞苷组合管理，我们确实观察到骨髓的反应在许多谁曾复发或难治的患者到阿扎胞苷。目前，我们预计从2015年中期的2期研究的中期数据。
     
    SHAPE CTCL计划：在5月，1B随机，安慰剂对照的形状临床研究阶段的安全性和有效性的数据，我们的外用HDAC抑制剂，在IA期-IIA皮肤T细胞淋巴瘤（CTCL）的调查，在皮肤科的年会提出会议和在临床肿瘤学会议的美国社会。我们正在推进捏成一个随机的二期临床试验早期CTCL。目前，我们预计围绕2015年底的数据。
     
    Birinapant/ conatumumab计划：招生继续在组合信号，寻求学习与conatumumab，Amgen公司的TRAIL受体激动剂抗体，在第三行卵巢癌。目前，我们预计各地的2014年底的数据。

第三季度2014年财务摘要

    现金，现金等价物和有价证券总额为65100000美元9月30日2014年，相比55100000美元于2013年12月31日。
     
    研究和开发费用为570万2014年第三季度，不包括20万美元的非现金股票补偿费用，相比210万美元在2013年的增长来自与临床试验相关的附加费用，主要结果在同一时期，包括我们的临床药物供应的生产和配方。
     
    总务和行政支出为200万美元，为2014年第三季度，不包括60万美元的非现金股票补偿费用，相比190万美元，2013年同期，但不包括30万美元的非现金基于股票的补偿费用。
     
    调整后的净亏损为2014年第三季度额为860万美元，较调整后净亏损为420万美元同期在2013年调整后净亏损不包括（i）非现金股票补偿费用; （二）非现金利息费用; （三）非现金公平值调整到公司的衍生负债：及（iv）非现金公平值调整到公认的形状收购2014年4月的部分对价的责任。
     
    已发行的2014年9月30日的股价分别为2230万，这还不包括优秀的股票期权购买3200000股，7.0亿股标的公司尚未行使可换股票据。

非GAAP财务指标

在所附的新闻稿中，该公司披露“调整后的净亏损”，“基本调整后每股普通股净亏损”和“调整后摊薄净亏损为每普通股”的某些历史时期，所有这些都被认为是“非GAAP财务措施“下，美国证券交易委员会的规则。 “非一般公认会计准则财务指标”定义为一个数值衡量一个公司的历史或未来的财务业绩，财务状况和现金流量的排除（或包括）金额，或受有排除的效果调整（或含）金额，包含在（或排除）的最直接可比的措施计算，并根据本公司的财务报表与会计准则提出。管理层并不打算的非GAAP财务措施，隔离或作为替代根据GAAP编制的结果要考虑的演示文稿。

对于提出的所有时期，本公司和解净亏损根据GAAP计算的，以调整后的净亏损。管理层认为，这些调整措施的介绍是对投资者有用，因为它提供了评估，公司的期间经营业绩和成果，以期在可比基础上没有根据GAAP计算，否则明显的一种手段，因为许多非现金，不频繁，或不寻常的指控，包括可能不会影响本公司的经营项目，不符合不寻常的非经常性项目的严格的会计准则定义。此外，在编制经营计划，预算和预测，并评估历史业绩，管理依赖，在某种程度上，对趋势的公司的历史业绩，不包括这些物品。最后，管理层认为这个演讲是在促进公司在同行业的其他公司，其中许多人排除类似项目之间的比较有用的。

关于TetraLogic制药公司

TetraLogic是临床阶段的生物制药公司，主要致力于发现和开发肿瘤和感染性疾病的新型小分子疗法。 TetraLogic有两个临床阶段的候选产品开发：birinapant和形状。 Birinapant当前正在阶段1和阶段2为血液恶性肿瘤和实体瘤的临床试验，并且也进入一个阶段1b/2a中的临床试验中乙型肝炎形状正进入第2阶段临床试验早期皮肤T-细胞淋巴瘤。

hao2014

大致搜索一下
应该是抗癌药
促使细胞凋亡
也许发现对乙肝也有一定效果，就如同替诺吧
希望有惊喜，但不宜过份乐观
细胞凋亡，听了有点怕的

咬牙硬挺

感谢分享

重韧

什么时候美肝年会被乙肝的占领，乙肝就解放了。就像去年的丙肝。以目前的情况。2020前应该是有希望的。。

StephenW

回复 重韧 的帖子

专家们同意你的看法.

AASLD: HCV Not Main Attraction Anymore

Published: Nov 6, 2014

By Michael Smith, North American Correspondent, MedPage Today






As the therapeutic picture for hepatitis C begins to settle down, the volume of abstracts on the topic is plateauing at the annual meeting of the American Association for the Study of Liver Diseases (AASLD).
That's not to say that new HCV therapies won't get a lot of play, according toGary Davis, MD, president of MedLogician Consulting of Ponte Vedra Beach, Fla., and secretary of the liver association.
But, he told MedPage Today in advance of the meeting, "there's a big shift toward fatty liver disease ... that reflects what people are seeing in the clinics."
Over the past several years, direct-acting HCV medications have stolen the show, with a host of new drugs and drug combinations working through the clinical trials process.
Now, with many of those drugs approved and others in the home stretch, meeting participants will be getting mature data, he said.
For instance, the meeting will get an update on the research that underpinned the recent approval of Gilead's ledipasvir/sofosbuvir combination, trade-named Harvoni.
And, Davis said, they can look forward to seeing the data that AbbVie is using to support its multidrug combination  --  dubbed 3D  --  which is now under review at the FDA.
"It's going to be pretty exciting to see where that's at," he said.
Gilead famously unleashed a firestorm of debate when it priced sofosbuvir (Sovaldi) at $1 a pilland Davis said participants might take all the drug-makers to task over pricing of HCV drugs.
"I'm anxious to hear the audience questions on this, what with the whole controversy over pricing," he said.
The picture in fatty liver disease is less clear than in HCV, but the condition is increasingly prevalent and researchers are now turning their attention to it, looking at the basic mechanisms as well as drug therapy.
It's a "hot area," he said.
Among the hot topics this year:

• The role of bariatric surgery in non-alcoholic steatohepatitis.
• Prednisone and pentoxifylline in alcoholic hepatitis
• Combinations of direct-acting HCV agents post-transplant.
• A recombinant enzyme in liposomal acid lipase deficiency.
  

Davis also said that there is increased interest in possible curative options for hepatitis B, an area of research that has been "stuck in the mud for years." HBV is tricky to cure, because the virus integrates itself into host cells and  --  rather like HIV  --  therapy has aimed at suppressing the virus rather than getting rid of it.
But several new compounds in the early stages of investigation aim to change that and the "HBV people are quite excited about it," Davis said.
As well, he said, participants will get results from a major trial of terlipressin, a drug for hepatorenal syndrome that is approved in several countries but not the U.S.
An initial report from the so-called REVERSE study  --  of terlipressin plus albumin versus albumin alone  --  will attract considerable interest, Davis said, since improvement in renal function in patients with the syndrome is correlated with improved survival.

AASLD：HCV不再是主要的吸引力

发布时间：2014年11月6日
由迈克尔·史密斯，北美的记者，MedPage今天



由于治疗图片为丙型肝炎开始定居下来，文摘的话题体积趋于稳定，在美国协会为肝脏疾病的研究（AASLD）年会上。

这并不是说，新的丙肝疗法不会得到很多的游戏，根据加里·戴维斯博士，蓬特韦德拉海滩，佛罗里达州的MedLogician咨询公司总裁肝脏协会的秘书。

不过，他告诉MedPage今天在会议中，“有一个大的转向性脂肪肝......这反映了人们所看到的诊所。”

在过去的几年中，直动HCV药物偷走了表演，有许多新的药物和药物组合，通过临床试验过程中的工作。

现在，许多这些批准的药品和其他在家里舒展，与会者会越来越成熟的数据，他说。

举例来说，本次会议将取得上支撑了近期Gilead公司ledipasvir/ sofosbuvir组合，以旧换新命名Harvoni批准研究的最新进展。

而且，戴维斯说，他们可以期待看到AbbVie使用，以支持其多重组合的数据 - 被称为3D - 这是目前正在审查在FDA。

“这将是非常令人兴奋地看到这是在，”他说。

吉利德著名发动了大规模的争论时，它的价格sofosbuvir（Sovaldi）在1美元丸和戴维斯表示，参与者可能把所有的药物制造商任务交给了丙型肝炎病毒药物的价格。

“我很想听听这个听众提出的问题，有什么用，整个争论的价格，”他说。

在脂肪肝的图片比HCV不太清楚，但条件是越来越普遍，研究人员正在把注意力转移到它，看着的基本机制，以及药物治疗。

这是一个“热区”，他说。

在今年的热门话题：

    减肥手术在非酒精性脂肪性肝炎的作用。
    强的松和己酮可可碱在酒精性肝炎
    的直接作用的HCV药物移植后的组合。
    重组酶在脂质体酸性脂肪酶缺乏症。

戴维斯还表示，有可能在选择治疗乙肝，研究已经在面积增加的兴趣“陷在泥里了多年。”乙肝病毒是棘手的治愈，因为病毒本身整合到宿主细胞 - 而不是像HIV - 疗法旨在抑制病毒，而不是摆脱它。

但在调查的初期阶段几个新的化合物旨在改变和“HBV的人都相当兴奋，”戴维斯说。

同时，他表示，与会者将得到特利加压素的一大考验，经核准在一些国家，但不是美国的药物用于肝肾综合征结果

从所谓的反向研究的初步报告 - 特利加压素以及白蛋白与单纯白蛋白 - 将吸引相当大的兴趣，戴维斯说，因为改善肾功能的患者综合征与相关改善生存。

StephenW

回复 hao2014 的帖子

没什么好怕.成人每天平均50到70之间十亿细胞的死亡是由于细胞凋亡的成人。

细胞凋亡（英语：apoptosis，源自希腊语：απόπτωσις，有堕落，死亡之意），為一種細胞程序性死亡。相对于细胞坏死（necrosis），细胞凋亡是细胞主动实施的。細胞凋亡一般由生理或病理性因素引起.而細胞壞死則主要為缺氧造成，两者可以很容易通过观察区分开来。在细胞凋亡过程中，细胞缩小，DNA被核酸内切酶降解成180bp-200bp片段屬於有層次之斷裂，（可以通过凝胶电泳证明），而细胞坏死时，细胞肿胀，细胞膜被破坏，通透性改变。细胞器散落到细胞间质，需要巨噬细胞去清除，结果是该局部组织发炎。相比起细胞坏死，细胞凋亡是更常见的细胞死亡形式。

咬牙硬挺

美国人加把劲啊

重韧

今年的美肝年会脂肪肝的研究提案爆棚，果然老美只是关心自己的问题。。肥胖率增加脂肪肝的几率，把这些都解决完了就轮到乙肝了。

StephenW

TetraLogic Pharmaceuticals Announces Results of Preclinical Studies in Hepatitis B


/releasedetail.cfm?ReleaseID=881518 Previous Release

MALVERN, Pa., Nov. 10, 2014 (GLOBE NEWSWIRE) -- TetraLogic Pharmaceuticals Corporation (Nasdaq:TLOG) today announced additional results from preclinical studies that demonstrated the ability of the SMAC-mimetic, birinapant, to clear Hepatitis B Virus (HBV) in mouse models.

In studies performed by Dr. Marc Pellegrini and his colleagues at the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, administration of birinapant to C57BL/6 mice hastened the clearance of HBV-DNA from blood and liver, and was associated with loss of HBV-surface antigen (HBsAg). Birinapant's effect occurred in a dose-related manner. This was associated with apoptosis of infected hepatocytes and transient elevation of liver transaminases. Normal hepatocytes were spared. The clearance of HBV-DNA was also seen with entecavir, and the two agents together were more effective than either agent alone. These results were confirmed using mice in which the targets of birinapant, the cIAPs, were ablated in the liver ("knock-out mice"). In C3H mice that do not spontaneously clear HBV, birinapant treatment resulted in loss of HBV-DNA, loss of HBsAg and the appearance of anti-HBsAg antibodies.


"These preclinical results provide a compelling rationale for TetraLogic's recently initiated clinical study in HBV" said J. Kevin Buchi, President and Chief Executive Officer of TetraLogic.

About the Walter and Eliza Hall Institute of Medical Research

The Walter and Eliza Hall Institute of Medical Research is Australia's oldest medical research institute. It is home to almost 750 researchers who are working to understand, prevent and treat diseases including infectious diseases, cancers and immune disorders. It is located in Parkville, Melbourne, and is closely associated with The University of Melbourne and The Royal Melbourne Hospital.

About TetraLogic Pharmaceuticals Corporation

TetraLogic is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases. TetraLogic has two clinical-stage product candidates in development: birinapant and SHAPE. Birinapant is currently being tested in Phase 1 and Phase 2 clinical trials for hematological malignancies and solid tumors, and is also being tested in a Phase 1b/2a clinical trial in hepatitis B. SHAPE is entering a Phase 2 clinical trial for early-stage Cutaneous T-cell Lymphoma.

临床前研究的乙肝TetraLogic制药宣布结果


/releasedetail.cfm?ReleaseID=881518先前版本

宾夕法尼亚，MALVERN，二〇一四年十一月一十日（中国商业电讯） -  TetraLogic制药公司（纳斯达克股票代码：TLOG）今天宣布，从临床前研究，证实了SMAC-模拟，birinapant的能力，其他结果以清除乙型肝炎病毒（HBV ）在小鼠模型中。

由马克·佩莱格里尼博士和他的同事在医学研究，墨尔本，澳大利亚，birinapant至C57BL/6小鼠的给药沃尔特和伊丽莎·霍尔研究所进行的研究赶紧从血液和肝脏中HBV-DNA的间隙，并与相关亏损HBV表面抗原（HBsAg）的。 Birinapant的效果发生在剂量相关的方式。这是与感染的肝细胞凋亡和肝转氨酶短暂升高有关。正常肝细胞也难幸免。 HBV-DNA的清除也被恩替卡韦，和两种试剂一起比单独使用任一药剂更有效。这些结果是用在其中birinapant的目标时，cIAPs，被烧蚀的肝（“敲除小鼠”）的小鼠证实。在C3H小鼠是不自发清晰的HBV，birinapant治疗导致HBV-DNA，损失的HBsAg与抗HBsAg抗体出现的损失。


“这些临床前研究结果为TetraLogic最近发起的临床研究HBV一个令人信服的理由”J.凯文步琪，总统和TetraLogic的首席执行官说。

有关医学研究的沃尔特和伊丽莎·霍尔研究所

医学研究的沃尔特和伊丽莎·霍尔研究所是澳大利亚最古老的医学研究机构。它是家庭对谁正在努力了解，预防和治疗疾病，包括感染性疾病，癌症和免疫系统疾病，几乎750研究者。它位于帕克维尔，墨尔本，并密切与墨尔本大学和皇家墨尔本医院有关。

关于TetraLogic制药公司

TetraLogic是临床阶段的生物制药公司，主要致力于发现和开发肿瘤和感染性疾病的新型小分子疗法。 TetraLogic有两个临床阶段的候选产品开发：birinapant和形状。 Birinapant当前正在阶段1和阶段2为血液恶性肿瘤和实体瘤的临床试验，并且也被在一个阶段1b/2a中的临床试验中乙型肝炎形状测试正在进入第2阶段临床试验早期皮肤T细胞淋巴瘤。